Advertisement
News
Advertisement

Eli Lilly and Company to Open a Diabetes-Focused Research Center in China

Tue, 11/02/2010 - 12:33am
Bio-Medicine.Org

INDIANAPOLIS, Nov. 2, 2010 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced today plans to open a research center focused on diabetes in China, where the incidence of the disease has reached epidemic proportions.

The center, to open in Shanghai in the second half of 2011, will focus on discovering new medicines to treat diabetes, and reflects both Lilly's longstanding leadership in this disease area and the priority Lilly places on improving the health of the Chinese people.  

"We are establishing this research center, first and foremost, to meet the growing unmet medical needs of those living in China with diabetes," said Jan Lundberg, Ph.D., executive vice president, science and technology, and president, Lilly Research Laboratories.  "This center will complement our existing network of collaborations in China and also will enable us to further gain the insights of China's talented scientists inside and outside of Lilly as we further explore a disease state in need of new and innovative therapies."

According to a recent article in The New England Journal of Medicine, an estimated 92 million people in China – almost 10 percent of the adult population – have diabetes(1), a number that is expected to increase in the coming decade due in large part to longer life expectancy, dietary changes and lack of exercise. Left untreated or undertreated, diabetes can lead to debilitating or potentially fatal complications, including heart disease, stroke, nerve damage, lower limb amputation, vision loss and kidney disease.

"Our strategy in China, and throughout the world, is to bring innovation to patients," said Jacques Tapiero, senior vice president and president of Lilly's emerging markets business area.  "By establishing a diabetes research center in China, Lilly will be better able to discover medicines that

'/>"/>

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading